| Jamie Lynn Giles, CNP | |
|
9400 Zane Ave N, Brooklyn Park, MN 55443-1814 | |
| (763) 762-6800 | |
| Not Available |
| Full Name | Jamie Lynn Giles |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 9400 Zane Ave N, Brooklyn Park, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396100046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | CNP4312 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Croix Psychiatric Llc | 9335288786 | 20 |
News Archive
New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.
Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.
A new Behavior Pain Assessment Tool (BPAT) provides a simple way to evaluate pain in critically ill patients—including those who aren't able to communicate their pain verbally, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
› Verified 3 days ago
| Entity Name | St Croix Psychiatric Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881849586 PECOS PAC ID: 9335288786 Enrollment ID: O20091125000166 |
News Archive
New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.
Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.
A new Behavior Pain Assessment Tool (BPAT) provides a simple way to evaluate pain in critically ill patients—including those who aren't able to communicate their pain verbally, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
› Verified 3 days ago
| Entity Name | Plymouth Psych Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003195942 PECOS PAC ID: 6800103490 Enrollment ID: O20150915000728 |
News Archive
New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.
Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.
A new Behavior Pain Assessment Tool (BPAT) provides a simple way to evaluate pain in critically ill patients—including those who aren't able to communicate their pain verbally, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie Lynn Giles, CNP 9400 Zane Ave N, Brooklyn Park, MN 55443-1814 Ph: (763) 762-6800 | Jamie Lynn Giles, CNP 9400 Zane Ave N, Brooklyn Park, MN 55443-1814 Ph: (763) 762-6800 |
News Archive
New research helps bridge an important gap in understanding schizophrenia, providing the best evidence to date that defects in the brain's white matter are a key contributor to the disease, which affects about 1 percent of people worldwide.
Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.
A new Behavior Pain Assessment Tool (BPAT) provides a simple way to evaluate pain in critically ill patients—including those who aren't able to communicate their pain verbally, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
› Verified 3 days ago